Sancy A. Leachman
No Rating Available
(Learn About Our Rating System)

Sancy A. Leachman, MD, PhD

Languages spoken: English

  • *Provider does not see patients in Utah*

    Sancy Leachman, MD, PhD, is an adjunct Professor in the Dept. of Dermatology at the University of Utah and based full-time at Oregon Health & Science University as the chair of Dermatology.

    She is a dermatologist using basic science research and state-of-the-art technology to combat skin cancer. Her clinical interests include skin cancers, especially melanoma, pigmentary disorders that result from abnormalities of melanocytes such as vitiligo, and genetic disorders that involve the skin such as pachyonychia congenita, Cowden syndrome, and other cutaneous cancer syndromes.

    Specialties

  • *Provider does not see patients in Utah*

    Sancy Leachman, MD, PhD, is an adjunct Professor in the Dept. of Dermatology at the University of Utah and based full-time at Oregon Health & Science University as the chair of Dermatology.

    She is a dermatologist using basic science research and state-of-the-art technology to combat skin cancer. Her clinical interests include skin cancers, especially melanoma, pigmentary disorders that result from abnormalities of melanocytes such as vitiligo, and genetic disorders that involve the skin such as pachyonychia congenita, Cowden syndrome, and other cutaneous cancer syndromes.

    Board Certification and Academic Information

    Academic Departments Dermatology -Adjunct

    Education history

    Fellowship Cutaneous Oncology - Yale University School of Medicine Fellow
    Dermatology - Yale - New Haven Hospital Resident
    Internship Internal Medicine - University of Texas Southwestern Medical School Intern
    University of Texas M.D., Ph.D.
    Undergraduate Liberal Arts - University of Texas at Austin Plan II B.A.

    Selected Publications

    Journal Article

    1. Curiel-Lewandrowski C, Kim CC, Swetter SM, Chen SC, Halpern AC, Kirkwood JM, Leachman SA, Marghoob AA, Ming ME, Grichnik JM (2012). Survival is not the only valuable end point in melanoma screening. J Invest Dermatol, 132(5), 1332-7. (Read full article)
    2. Teerlink C, Farnham J, Allen-Brady K, Camp NJ, Thomas A, Leachman S, Cannon-Albright L (2012). A unique genome-wide association analysis in extended Utah high-risk pedigrees identifies a novel melanoma risk variant on chromosome arm 10q. Hum Genet, 131(1), 77-85. (Read full article)
    3. Sondak VK, Leachman SA (2011). Individualizing follow-up for patients with early-stage melanoma. J Clin Oncol, 29(35), 4606-8. (Read full article)
    4. Moos PJ, Olszewski K, Honeggar M, Cassidy P, Leachman S, Woessner D, Cutler NS, Veranth JM (2011). Responses of human cells to ZnO nanoparticles: a gene transcription study. Metallomics, 3(11), 1199-211. (Read full article)
    5. Jenkins NC, Liu T, Cassidy P, Leachman SA, Boucher KM, Goodson AG, Samadashwily G, Grossman D (2011). The p16(INK4A) tumor suppressor regulates cellular oxidative stress. Oncogene, 30(3), 265-74. (Read full article)
    6. Leaf SL, Aspinwall LG, Leachman SA (2010). God and Agency in the Era of Molecular Medicine: Religious Beliefs Predict Sun-Protection Behaviors Following Melanoma Genetic Test Reporting. Arch Psychol Relig, 32, 1-26.
    7. Kadekaro AL, Leachman S, Kavanagh RJ, Swope V, Cassidy P, Supp D, Sartor M, Schwemberger S, Babcock G, Wakamatsu K, Ito S, Koshoffer A, Boissy RE, Manga P, Sturm RA, Abdel-Malek ZA (2010). Melanocortin 1 receptor genotype: an important determinant of the damage response of melanocytes to ultraviolet radiation. FASEB J, 24(10), 3850-60. (Read full article)
    8. Leachman SA, Hickerson RP, Schwartz ME, Bullough EE, Hutcherson SL, Boucher KM, Hansen CD, Eliason MJ, Srivatsa GS, Kornbrust DJ, Smith FJ, McLean WI, Milstone LM, Kaspar RL (2010). First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. Mol Ther, 18(2), 442-6. (Read full article)
    9. Leachman SA, Carucci J, Kohlmann W, Banks KC, Asgari MM, Bergman W, Bianchi-Scarra G, Brentnall T, Bressac-de Paillerets B, Bruno W, Curiel-Lewandrowski C, de Snoo FA, Debniak T, Demierre MF, Elder D, Goldstein AM, Grant-Kels J, Halpern AC, Ingvar C, Kefford RF, Lang J, MacKie RM, Mann GJ, Mueller K, Newton-Bishop J, Olsson H, Petersen GM, Puig S, Rigel D, Swetter SM, Tucker MA, Yakobson E, Zitelli JA, Tsao H (2009). Selection criteria for genetic assessment of patients with familial melanoma. J Am Acad Dermatol, 61(4), 677.e1-14. (Read full article)
    10. Florell SR, Boucher KM, Garibotti G, Astle J, Kerber R, Mineau G, Wiggins C, Noyes RD, Tsodikov A, Cannon-Albright LA, Zone JJ, Samlowski WE, Leachman SA (2005). Population-based analysis of prognostic factors and survival in familial melanoma. J Clin Oncol, 23(28), 7168-77. (Read full article)

    Patent

    1. Pershing LK, Leachman SA (2005). Skin Type Assessment and Nevi Screening for Skin Cancer with a Non-invasive Portable Reflectance Spectrophotometer, Patent Pending, United States. U.S. Patent No. 11-115-646. Washington, D.C.:U.S. Patent and Trademark Office.
    2. Pershing LK, Leachman SA (2004). Method for Detection and Characterization of Premalignant Transformation (Markers of Melanoma Predisposition and Transformation), Patent Pending, International. U.S. Patent No. PCT/US2004/013318. Washington, D.C.:U.S. Patent and Trademark Office.

  • News & Podcasts

    News